195 related articles for article (PubMed ID: 21917837)
1. Commentary: Does additional benefit justify additional costs of insulin analogues?
Sawicki PT
BMJ; 2011 Sep; 343():d5858. PubMed ID: 21917837
[No Abstract] [Full Text] [Related]
2. [Short acting insulin analogues for type 2 diabetes. Unnecessary additional expenditure or valuable added benefit? Interview by Böhm Sanja].
Hess R; Kerner W
Dtsch Med Wochenschr; 2006 Oct; Suppl 1():36-7. PubMed ID: 17595817
[No Abstract] [Full Text] [Related]
3. Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting.
Mittendorf T; Smith-Palmer J; Timlin L; Happich M; Goodall G
Diabetes Obes Metab; 2009 Nov; 11(11):1068-79. PubMed ID: 19732121
[TBL] [Abstract][Full Text] [Related]
4. The prickly problem of access to insulin.
Cohen D
BMJ; 2011 Sep; 343():d5782. PubMed ID: 21917833
[No Abstract] [Full Text] [Related]
5. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
von Ferber L; Köster I; Hauner H
Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
[TBL] [Abstract][Full Text] [Related]
6. ["The Lantus Case": What is the benefit of health economics?].
Schöffski O
Dtsch Med Wochenschr; 2010 May; 135(20):1033-5. PubMed ID: 20461663
[No Abstract] [Full Text] [Related]
7. The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics.
Levin P
Diabetes Obes Metab; 2008 Jul; 10 Suppl 2():66-75. PubMed ID: 18577158
[TBL] [Abstract][Full Text] [Related]
8. [New drugs for diabetes treatment. Fast-acting insulin analogues].
Forst T
Pharm Unserer Zeit; 2001; 30(2):118-23. PubMed ID: 11279981
[No Abstract] [Full Text] [Related]
9. [Health economic consequences of insulin analogues in the treatment of type 1 diabetes in Denmark].
Palmer AJ; Lammert M; Hermansen K
Ugeskr Laeger; 2008 Apr; 170(15):1250-4. PubMed ID: 18433583
[TBL] [Abstract][Full Text] [Related]
10. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
[TBL] [Abstract][Full Text] [Related]
11. PHARMAC and long-acting insulin analogues: a poor man's insulin pump--but not available to the poor man.
Krebs J
N Z Med J; 2005 Aug; 118(1221):U1641. PubMed ID: 16138177
[TBL] [Abstract][Full Text] [Related]
12. ["The Lantus case": and yet it does move (or not?)].
Schöffski O
Dtsch Med Wochenschr; 2010 Sep; 135(36):1755-6. PubMed ID: 20812163
[No Abstract] [Full Text] [Related]
13. Comment and reply on: Relative efficacy/effectiveness and relative costs of treatment with insulin glargine and insulin detemir.
Freemantle N; Stella P; Munro V
Curr Med Res Opin; 2007 Aug; 23(8):1761-2; author reply 1762-4. PubMed ID: 17588305
[No Abstract] [Full Text] [Related]
14. Insulin analogues: a step forward in the care in diabetes.
Holt RI
Diabetes Obes Metab; 2009 Jan; 11(1):1-4. PubMed ID: 19120430
[No Abstract] [Full Text] [Related]
15. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
[TBL] [Abstract][Full Text] [Related]
16. [Insulin analogues--which dimension should be discussed?].
Verspohl EJ
Med Monatsschr Pharm; 2006 Jun; 29(6):198-9. PubMed ID: 16792195
[No Abstract] [Full Text] [Related]
17. [Are the short-acting insulin analogs superfluous?].
Arand M
MMW Fortschr Med; 2006 Mar; 148(11):17. PubMed ID: 16612957
[No Abstract] [Full Text] [Related]
18. More from PHARMAC on long-acting insulin analogues: insulin glargine now funded.
Moodie P
N Z Med J; 2006 Jun; 119(1236):U2040. PubMed ID: 16807582
[No Abstract] [Full Text] [Related]
19. An overview of insulin glargine.
Home PD; Ashwell SG
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S57-63. PubMed ID: 12324987
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetic characteristics and clinical indication of insulin analogues].
Matsuhisa M; Kuroda A
Nihon Rinsho; 2012 May; 70 Suppl 3():658-63. PubMed ID: 22768594
[No Abstract] [Full Text] [Related]
[Next] [New Search]
